Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Kelly

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|August 25, 2012
Metabolism of patupilone in patients with advanced solid tumor malignanciesKevin R Kelly, Markus Zollinger, Frédéric Lozac'h, et al.
Biomedical Chromatography : BMC|July 27, 2022
Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometryAmanda B Kagan, Nicole M Anders, Avelina Hemingway, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2016
Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairmentKevin R Kelly, Nashat Gabrail, Steven Weitman, et al.
Journal of Clinical Pathology|April 21, 2010
Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficientlyRonan T Swords, Kevin R Kelly, Stephen C Cohen, et al.
Cells|July 25, 2025
p47phox: A Central Regulator of NADPH Oxidase Function and a Promising Therapeutic Target in Redox-Related DiseasesMadison E Gamble, Sruthi Sureshkumar, Maria Janina Carrera Espinoza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2013
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancerSteffan T Nawrocki, Kevin R Kelly, Peter G Smith, et al.
Cancers|June 13, 2025
Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic DrugsAndrew J Kinloch, Faiyaz Rahman, Bahriye Karakas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 12, 2016
Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutationsImran N Siddiqi, Julia Friedman, Keegan Q Barry-Holson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Blood|March 6, 2010
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemiaRonan T Swords, Kevin R Kelly, Peter G Smith, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|August 25, 2012
Metabolism of patupilone in patients with advanced solid tumor malignanciesKevin R Kelly, Markus Zollinger, Frédéric Lozac'h, et al.
Biomedical Chromatography : BMC|July 27, 2022
Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometryAmanda B Kagan, Nicole M Anders, Avelina Hemingway, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2016
Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairmentKevin R Kelly, Nashat Gabrail, Steven Weitman, et al.
Journal of Clinical Pathology|April 21, 2010
Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficientlyRonan T Swords, Kevin R Kelly, Stephen C Cohen, et al.
Cells|July 25, 2025
p47phox: A Central Regulator of NADPH Oxidase Function and a Promising Therapeutic Target in Redox-Related DiseasesMadison E Gamble, Sruthi Sureshkumar, Maria Janina Carrera Espinoza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2013
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancerSteffan T Nawrocki, Kevin R Kelly, Peter G Smith, et al.
Cancers|June 13, 2025
Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic DrugsAndrew J Kinloch, Faiyaz Rahman, Bahriye Karakas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 12, 2016
Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutationsImran N Siddiqi, Julia Friedman, Keegan Q Barry-Holson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Blood|March 6, 2010
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemiaRonan T Swords, Kevin R Kelly, Peter G Smith, et al.
Pageof 5